EcoDrugPlus

Pim-2 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSCHOG00000000739
Gene Symbol: PIM2
1 Cross references
115 Possible Orthologues:

Ros Proto-Oncogene 1, Receptor Tyrosine Kinase

Ensembl ID : ENSCHOG00000009679
Gene Symbol: ROS1
1 Cross references
125 Possible Orthologues:

Raf-1 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSCHOG00000001052
Gene Symbol: RAF1
1 Cross references
224 Possible Orthologues:

Rho Associated Coiled-Coil Containing Protein Kinase 1

Ensembl ID : ENSCHOG00000000557
Gene Symbol: ROCK1
1 Cross references
211 Possible Orthologues:

Rho Associated Coiled-Coil Containing Protein Kinase 2

Ensembl ID : ENSCHOG00000006470
Gene Symbol: ROCK2
1 Cross references
298 Possible Orthologues:

Tek Receptor Tyrosine Kinase

Ensembl ID : ENSCHOG00000006936
Gene Symbol: TEK
1 Cross references
166 Possible Orthologues:

Ttk Protein Kinase

Ensembl ID : ENSCHOG00000011192
Gene Symbol: TTK
1 Cross references
205 Possible Orthologues:

Udp-Glucose Ceramide Glucosyltransferase

Ensembl ID : ENSCHOG00000005023
Gene Symbol: UGCG
1 Cross references
212 Possible Orthologues:

Wee1 G2 Checkpoint Kinase

Ensembl ID : ENSCHOG00000013593
Gene Symbol: WEE1
1 Cross references
227 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSCHOG00000010130
Gene Symbol: ADORA2A
1 Cross references
264 Possible Orthologues:

Adrenoceptor Alpha 1a

Ensembl ID : ENSCHOG00000010944
Gene Symbol: ADRA1A
1 Cross references
201 Possible Orthologues:

Adrenoceptor Alpha 1b

Ensembl ID : ENSCHOG00000006156
Gene Symbol: ADRA1B
1 Cross references
265 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).